Tesamorelin stimulates the body’s growth-hormone release and raises IGF-1. EGRIFTA products reduce excess abdominal fat in adults with HIV-associated lipodystrophy; clinics and community discussions also explore body composition and different weekly patterns.
Research focus: Visceral abdominal fat and growth-hormone signaling.
Choose a compound to open its research, documentation and calculator.
EGRIFTA: excess abdominal fat in adults with HIV-associated lipodystrophy.
Official source ↗Single-dose subcutaneous studies in healthy subjects. WR and SV have distinct formulations. The older 26-minute reference value is not used for these products.
Half-life describes concentration falling by half. It does not set a dosing interval, a storage period or a drug-test detection window.
Kinetics source ↗WR uses its supplied bacteriostatic water; SV uses its supplied sterile water. These are different preparations, concentrations and usable periods.
Bacteriostatic water contains a preservative; plain sterile water does not. Preservative presence does not by itself establish compatibility or a mixed medicine’s usable period.
Preparation source ↗The label instructions below apply to the named prescription products and their indications. A matching peptide name on another vial does not establish an equivalent formulation.
Check that a source concerns the same molecule, formulation, route and population. A study of cells, animals or a different product cannot confirm the contents of a vial.
Human trials, current WR/SV labels and separately attributed clinic and community reports.
Tesamorelin binds GHRH receptors and stimulates growth hormone release. GH then increases insulin-like growth factor 1 (IGF-1). It acts upstream of GH rather than supplying GH itself.
Mechanism in the product label · section 12.1 ↗Visceral adipose tissue (VAT) is fat around the internal organs, different from fat just beneath the skin. The pivotal studies measured abdominal VAT by CT; a VAT percentage is not a percentage of total body weight lost.
Explore the pivotal trial →What to watch in the evidence: the label calls for monitoring IGF-1 and glucose. Fluid retention, joint pain and carpal tunnel symptoms are recognized concerns; short-term trial averages do not remove individual risk. Label safety and monitoring · sections 4–5 ↗
Learn to read a study →Each entry keeps one schedule’s amount, frequency and cycle together. Community references, individual reports, clinical trials and prescription products describe different kinds of use. A missing duration or break stays marked as not reported.
Amounts describe mass in mg or mcg. Syringe units describe volume and depend on concentration. A cycle break is different from days off within a week.
Choose an option to explore its amounts, timing and cycle.
Approved for excess abdominal fat in adults with HIV-associated lipodystrophy. “WR” refers to weekly reconstitution, not weekly injections.
WR and SV have different doses and preparation instructions.
Historical 2 mg formulation; do not substitute this amount for current WR or SV.
| When | Amount & frequency |
|---|---|
| First 2 weeks | 1 mg daily |
| After 2 weeks · proposed | 2 mg daily |
A proposed community schedule. It is separate from the WR and SV prescription formulations.
Community identifies source origin. It does not certify independent funding, medical credentials or the strength of a claim. Source types distinguish published reports, professional explanations and public discussions.
Explore reports, explanations and discussions from medical practices, researchers, suppliers and community members. The badges identify the source’s origin and evidence type.
How to read these source labels →No cited comparison validates equivalence to the pivotal daily trials or prevention of receptor desensitization.
Source relationship: Commercial aesthetics and wellness provider.
The clinic describes intermittent weekly use and a break between treatment periods. The quick card contrasts it with daily EGRIFTA labels and trials.
Clinic proposal · different from approved daily schedules
This is a discussion, not a registered trial or a published clinical dataset. Product identity, doses, measurements and medical histories are not independently verified. It does not establish a starter regimen, equivalent results with days off, mandatory bedtime fasting or a universal reconstitution method.
Source relationship: Public pseudonymous account. Clinical credentials, funding and conflicts of interest are not verified; a forum badge does not establish independent research.
This discussion compares 1 mg and 2 mg, daily and five-on/two-off schedules, bedtime fasting, tolerability and a proposed 5 mg/mL preparation. Replies describe differing experiences. These topics are checked against trial reports and product labels in this guide.
Forum discussion · self-reports and proposed protocols · credentials unverified
A peptide name and vial mass cannot determine a compatible diluent, powder displacement, storage temperature or discard date. Follow the exact product’s instructions and your pharmacist’s directions.
The injection guide concerns clinician-prescribed subcutaneous medicines; it does not establish that a research-labeled material can be injected.
Start with the formulation: dry powder, prepared solution, pen, tablet and topical product can have different instructions.
A research vial’s mass and a Reddit recipe do not verify compatible diluent, stability or usable doses. Follow the exact product documentation. If a solution is cloudy, discolored or contains particles, the product labels say not to use it; adding other chemicals is not an approved troubleshooting step.
The thread’s proposed 5 mg/mL is a concentration example, not the concentration of either current EGRIFTA product. Here is what the product labels actually specify:
Swirl gently; do not shake. Use only clear, colorless solution without particles. Keep the prepared vial at 20–25°C (68–77°F); do not refrigerate or freeze. The diluent bottle’s 28-day discard rule is separate from the medicine’s seven-day rule.
WR preparation, storage and illustrated instructions ↗Roll gently in the hands for 30 seconds; do not shake. Use only clear, colorless solution without particles. Do not refrigerate or freeze the prepared solution. SV does not follow WR’s seven-day storage workflow.
SV preparation, storage and illustrated instructions ↗If a documented final solution is 5 mg/mL, a hypothetical 2 mg target corresponds to 0.4 mL = 40 U-100 scale units. The same concentration can be described by different mass / final-volume pairs:
These ratios do not specify how much liquid to add, which liquid is compatible or how long a vial can be used. For a product with a labeled concentration, use Advanced → Use a documented concentration (mg/mL) in the calculator. WR’s label specifies 8 mg/mL; dividing 11.6 by the 1.3 mL added would give the wrong labeled concentration.
Explore the concentration arithmetic ↓General health habits and consistent observations help you assess changes. They are not evidence that a peptide’s effects will be amplified.
Choose activity that fits your health and ability. Aerobic movement and muscle-strengthening work are part of general adult activity guidance.
CDC · adult activity ↗Use a regular sleep/wake schedule and note changes in sleep quality alongside symptoms or training.
CDC · sleep habits ↗What to record: Track food intake, appetite, activity and tolerability together. Appetite control should still leave room for adequate meals; review persistent eating difficulties with the treating clinician.
Check dates are editorial references, not a medical review certificate. Labels and evidence can change; consult the linked current document.
The calendar compares frequency, not effectiveness. Neither a weekly total nor a short plasma half-life can predict fat loss, IGF-1 response or tolerability. These are research questions, not a selected regimen.
The original phase 3 programs used 2 mg subcutaneously every day with the historical formulation: 26 weeks of randomized treatment followed by a 26-week extension. The pooled report included 806 participants (543 tesamorelin, 263 placebo), rather than the 740 quoted in the forum post. Read the pooled trial report ↗
The pivotal daily schedule underlies the clinical results. Participants continuing treatment maintained VAT reductions through week 52.
This is discussed in the thread; the labels and trials reviewed here do not establish comparable outcomes for this pattern. Five administrations are two fewer per week, but the effect on VAT or IGF-1 cannot be calculated from that count.
Read the community discussion ↗Current WR and SV doses are lower in milligrams because their labels describe exposure comparable to the older 2 mg formulation. They are not interchangeable. “WR” means weekly reconstitution; the labeled injection schedule remains daily. WR label · sections 2 and 12.3 ↗ · SV label ↗
These summaries distinguish the thread’s proposals from the reviewed original reports and product labels. A forum post can suggest a useful research question without providing a verified clinical protocol. No trial directly comparing daily and five-on/two-off was identified in this review.
The thread proposes 1 mg initially, then 2 mg. A published 53-person, 12-week trial did compare 1 mg, 2 mg and placebo in type 2 diabetes. It examined metabolic safety, not equivalent VAT loss or a starter protocol for the wider community.
Read the dose-comparison study →The post proposes bedtime use while fasted. The reviewed labels do not specify mandatory bedtime or a two-hour fasting window. They report mean plasma half-lives of 8 minutes for SV and 11 minutes for WR in healthy subjects; that does not establish the best time of day or justify days off.
SV pharmacokinetics · section 12.3 ↗ · WR label ↗Perfect B describes 1 mg on five days each week, for three months followed by two months off. It also discusses combinations with ipamorelin; that does not establish added benefit or the safety of combining the compounds.
Its “25 units” amount corresponds to 1 mg only at 4 mg/mL on a U-100 syringe. It is not a universal tesamorelin conversion. The clinic’s cycle rationale is not evidence that breaks prevent receptor desensitization.
Read the original clinic explanation ↗Competitive sport: the 2026 WADA list names tesamorelin under S2.2.4, prohibited at all times. Athletes using prescribed treatment should consult their anti-doping organization about therapeutic-use exemption requirements. WADA list · S2 ↗
Duration and stopping: daily study periods of 26–52 weeks are not a universal “cycle.” The label describes VAT reaccumulation after withdrawal and says long-term cardiovascular safety is not established. Waist measurements and self-reports alone cannot distinguish VAT from other body changes. Clinical studies and limitations of use ↗
Selected studies and clinical reports, with the question, context and limitations close at hand.
Could stimulating GH release reduce visceral abdominal fat in adults with HIV?
Did tesamorelin affect fat in the liver as well as around internal organs?
What did a direct comparison of 1 mg, 2 mg and placebo actually measure?
Could tesamorelin reduce liver fat in people with HIV and fatty liver disease?
Opening values and worked examples illustrate arithmetic; they are not preparation instructions or recommended amounts. Selecting a compound labels the calculation and does not supply a dose or powder-volume correction.
Enter the documented vial mass, preparation information and target amount to see how mass and volume connect.
20 mg in an assumed final 1 mL gives 20 mg/mL. An entered 1 mg corresponds to 0.05 mL, or 5 U-100 units, with 20 theoretical portions before losses.
Estimate · assumes 1 mL added = total volume
1,000 mcg
Theoretical · before losses
0.2 mL
After 5 full doses
Illustration only · calculated value, without rounding
Saved calculations stay on this device.
Concentration = mass ÷ final volume
5 mg ÷ 1 mL = 5 mg/mLVolume = target mass ÷ concentration
1 mg ÷ 5 mg/mL = 0.2 mLU-100 markings = volume × 100
0.2 mL × 100 = 20 unitsComplete portions = floor(vial mass ÷ amount per portion).
Displayed numbers are rounded for readability; the calculation uses unrounded values.
Already have the concentration? Find the matching mL and U-100 syringe reading.
Need the concentration first? Use the Reconstitution tab.
5units
0.05 mL · 0.25 mg
0.25 mg ÷ 5 mg/mL = 0.05 mLU-100 units = mL × 100Example inputs are editable. The reading is calculated without rounding to a physical graduation.
Convert mass or liquid volume. U-100 markings always refer to a 100-units-per-mL scale.
1,000mcg
For mass → syringe volume, switch to Dosage and enter a concentration.